NDANASALSPRAY, METERED
Approved
Aug 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ASTEPRO is an azelastine hydrochloride nasal spray, a selective H1-receptor antagonist indicated for allergic rhinitis. It delivers rapid symptom relief through intranasal administration, targeting histamine-mediated allergic responses in the nasal cavity.
LOE Approaching
As loss-of-exclusivity approaches, commercial teams should expect portfolio contraction and redeployment to growth-stage assets; this is a consolidation opportunity for cost-focused roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ASTEPRO offers limited career momentum as a mature, loss-of-exclusivity asset under Viatris stewardship. Roles on this product focus on defending market share and managing generic transition rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on ASTEPRO at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.